URGN
UroGen Pharma Ltd.
$27.25
+1.49%
$1.4B
No data for this timeframe.
Vol
Market Cap$1.4B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (86%)
Insider Activity0B / 4S
Insider Net $-$531.1K
SEC Reports5
Press Releases2
Recent Activity
Jun 8, 2026
Insider
Schoenberg Mark sold 10,000 shares
Chief Medical Officer @ $0.00 ($0.00)
Jun 8, 2026
Insider
Schoenberg Mark sold 5,222 shares
Chief Medical Officer @ $27.30 ($142.6K)
Jun 8, 2026
Insider
Schoenberg Mark sold 10,000 shares
Chief Medical Officer @ $0.00 ($0.00)
Jun 5, 2026
other
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>PRINCETON, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech
Jun 2, 2026
SEC
UroGen Pharma settled patent litigation with Teva over Jelmyto (mitomycin) for pyelocalyceal solution. Under the settlem
8-K — Impact 5/10
May 16, 2026
SEC
HC Wainwright upgrades URGN to Buy — PT $50 (+67%)
ANALYST-UPGRADE — Impact 1/10
Apr 16, 2026
SEC
HC Wainwright upgraded URGN to Buy from Neutral with a $50 price target, matching its prior target. The firm has a histo
ANALYST-UPGRADE — Impact 5/10
Mar 2, 2026
Press
UroGen Pharma reported full-year 2025 financial results with total revenue of $109.8 million, up 21% YoY, driven by the
Impact 6/10
Price Targets
$36.88
+30.9% upside
Strong Buy
Current $28.18
Low $18.00
Median $40.00
High $45.00
8 analysts
$18.00
$45.00
Analyst Ratings
6Strong Buy
6Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 3, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 18, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 11, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| May 7, 2026 | Oppenheimer | MAINTAIN | Outperform → Outperform |
| Mar 31, 2026 | D. Boral Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.30 ▲ +15.6% | $-0.61 — $-0.21 | 71% YoY | 8 |
| Next Q | $-0.11 ▲ +45.5% | $-0.37 — $0.12 | 84% YoY | 8 |
| Current FY | $-0.91 ▲ +16.8% | $-1.70 — $-0.26 | 72% YoY | 8 |
| Next FY | $1.23 ▲ +4.9% | $0.25 — $2.79 | 236% YoY | 8 |
Latest Reports
BULLISH
ANALYST-UPGRADE
1/10
HC Wainwright upgrades URGN to Buy — PT $50 (+67%)
May 16, 2026
BULLISH
ANALYST-UPGRADE
5/10
HC Wainwright upgraded URGN to Buy from Neutral with a $50 price target, matching its prior target. The firm has a histo
Apr 16, 2026
MIXED
Press
6/10
UroGen Pharma reported full-year 2025 financial results with total revenue of $109.8 million, up 21% YoY, driven by the
Mar 2, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 8, 2026 | Schoenberg Mark | M | $0.00 |
| Jun 8, 2026 | Schoenberg Mark | SELL | $142.6K |
| Jun 8, 2026 | Schoenberg Mark | M | $0.00 |
| May 26, 2026 | Robinson James | M | $0.00 |
| May 26, 2026 | Robinson James | M | $0.00 |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
4 unique insiders with 4 transactions. Net insider value: -$531.1K ($0.00 bought, $531.1K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 8, 2026 | Schoenberg Mark | Chief Medical Officer | M | 10,000 | $0.00 | $0.00 |
| Jun 8, 2026 | Schoenberg Mark | Chief Medical Officer | SELL | 5,222 | $27.30 | $142.6K |
| Jun 8, 2026 | Schoenberg Mark | Chief Medical Officer | M | 10,000 | $0.00 | $0.00 |
| May 26, 2026 | Robinson James A. Jr. | Director | M | 2,000 | $0.00 | $0.00 |
| May 26, 2026 | Robinson James A. Jr. | Director | M | 2,000 | $0.00 | $0.00 |
| May 8, 2026 | Schoenberg Mark | Chief Medical Officer | SELL | 10,000 | $30.00 | $300.0K |
| Feb 3, 2026 | Smith Jason Drew | General Counsel | SELL | 2,654 | $19.69 | $52.3K |
| Feb 3, 2026 | Schoenberg Mark | Chief Medical Officer | SELL | 1,844 | $19.69 | $36.3K |
| Jan 31, 2026 | Smith Jason Drew | General Counsel | M | 5,500 | $0.00 | $0.00 |
| Jan 31, 2026 | Smith Jason Drew | General Counsel | M | 5,500 | $0.00 | $0.00 |
| Jan 31, 2026 | Smith Jason Drew | General Counsel | A | 32,609 | $0.00 | $0.00 |
| Jan 31, 2026 | Degnan Chris | Chief Financial Officer | A | 32,609 | $0.00 | $0.00 |
| Jan 31, 2026 | Schoenberg Mark | Chief Medical Officer | M | 3,333 | $0.00 | $0.00 |
| Jan 31, 2026 | Schoenberg Mark | Chief Medical Officer | M | 3,333 | $0.00 | $0.00 |
| Jan 31, 2026 | Schoenberg Mark | Chief Medical Officer | A | 20,000 | $0.00 | $0.00 |
| Feb 26, 2025 | Robinson James A. Jr. | M | 2,000 | $0.00 | $0.00 |
5 SEC filing reports analyzed. Sentiment: 3 bullish, 1 bearish, 0 mixed, 1 neutral. Avg impact: 5.0/10.
BULLISH
ANALYST-UPGRADE
5/10
HC Wainwright upgraded URGN to Buy from Neutral with a $50 price target, matching its prior target.
Apr 16, 2026
BULLISH
ANALYST-UPGRADE
1/10
HC Wainwright upgrades URGN to Buy — PT $50 (+67%)
May 16, 2026
NEUTRAL
8-K
5/10
UroGen Pharma settled patent litigation with Teva over Jelmyto (mitomycin) for pyelocalyceal solutio
Jun 2, 2026
BULLISH
PRESS-RELEASE
7/10
UroGen reported Q1 2026 total revenue of $51.0M (+152% YoY), driven by ZUSDURI's launch ($29.2M, +10
May 6, 2026
BEARISH
PRESS-RELEASE
7/10
UroGen Pharma reported Q4 2025 EPS of -$0.54, missing consensus of -$0.48 by 12.5%. No revenue figur
Apr 29, 2026
Current analyst consensus: Strong Buy (86% buy). Based on 14 analysts: 6 strong buy, 6 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$36.88 mean target
+30.9% upside
Strong Buy (1.43)
$18.00 Low
$45.00 High
| Metric | Value |
|---|---|
| Current Price | $28.18 |
| Target Low | $18.00 |
| Target Mean | $36.88 |
| Target Median | $40.00 |
| Target High | $45.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (1.43) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.30 | $-0.61 | $-0.21 | 71.1% | +15.6% | 6↑ 3↓ | $0.1B | 154.3% | 8 |
| Next Q 2026-09-30 |
$-0.11 | $-0.37 | $0.12 | 83.7% | +45.5% | 5↑ 1↓ | $0.1B | 163.3% | 8 |
| Current FY 2026-12-31 |
$-0.91 | $-1.70 | $-0.26 | 71.6% | +16.8% | 6↑ 3↓ | $0.3B | 142.2% | 8 |
| Next FY 2027-12-31 |
$1.23 | $0.25 | $2.79 | 235.8% | +4.9% | 4↑ 3↓ | $0.4B | 57.8% | 8 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.304 | |
| 7d ago | $-0.287 | -0.017 |
| 30d ago | $-0.360 | +0.056 |
| 60d ago | $-0.366 | +0.063 |
| 90d ago | $-0.366 | +0.063 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 3, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 18, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 11, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 7, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Mar 31, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Mar 2, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 23, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
| Jan 5, 2026 | D. Boral Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 6 | 2 | 0 | 0 | 86% | |
| May 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% | |
| Apr 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% | |
| Mar 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% | |
| Feb 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% | |
| Jan 1, 2026 | 5 | 7 | 2 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 5, 2026
other
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>PRINCETON, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializi
May 15, 2026
other
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
UroGen Announces 36 mo DOR from the UTOPIA trial studying UGN-103 for the treatment of LG-IR-NMIBC
May 7, 2026
earnings_calendar
URGN Q1 2026 Earnings Scheduled — 2026-05-07
May 7, 2026
short_volume
Short Volume: URGN — 63.2% short (0.3M / 0.5M)
Short: 322,860 | Exempt: 622 | TRF Vol: 510,475 | Short Ratio: 63.2% | Off-exchange volume (dark pool + OTC)
May 6, 2026
earnings
UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights
<p align="justify">PRINCETON, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing an
May 6, 2026
short_interest
FTD: URGN — 63,500 shares ($1.5M) failed to deliver
Settlement: 20260506, Price: $23.83, FTD Value: $1,513,205, UROGEN PHARMA LTD ORD SHS (ISR
May 6, 2026
earnings_calendar
URGN Q1 2026 Earnings Scheduled — 2026-05-06
Apr 29, 2026
earnings
UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026
Conference Call and Webcast Scheduled for Wednesday, May 6th, 2026, at 10:00 AM ET <pre>Conference Call and Webcast Scheduled for Wednesday, May 6th,
Mar 30, 2026
fda
Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI
UroGen announces that the pivotal ENVISION 24 mo. Duration of Response date has been published online in The Journal of Urology.
Mar 13, 2026
other
UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence
BCAN Launches News Faces of Bladder Cancer Report based on a survey of 1,100 patients.
Mar 6, 2026
other
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>PRINCETON, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializ
Mar 3, 2026
short_interest
FTD: URGN — 38,403 shares ($0.7M) failed to deliver
Settlement: 20260303, Price: $19.02, FTD Value: $730,425.06, UROGEN PHARMA LTD ORD SHS (ISR
Mar 2, 2026
earnings
UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results
<p>PRINCETON, N.J., March 02, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializ
Mar 2, 2026
earnings
UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors
<p align="center"><em>Opportunistic refinancing meaningfully reduces cost of capital with 8.25% fixed interest rate and extends amortization period to
Mar 2, 2026
earnings_calendar
URGN Q4 2025 Earnings After Market Close — 2026-03-02